Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Change in Cash (2016 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Change in Cash for 13 consecutive years, with $5.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Cash rose 110.23% to $5.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $47.0 million, a 179.31% increase, with the full-year FY2025 number at $47.0 million, up 179.31% from a year prior.
  • Change in Cash was $5.0 million for Q4 2025 at Iovance Biotherapeutics, down from $25.7 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $311.8 million in Q1 2023 to a low of -$253.5 million in Q2 2023.
  • A 3-year average of -$5.8 million and a median of -$17.3 million in 2025 define the central range for Change in Cash.
  • Peak YoY movement for Change in Cash: crashed 271.22% in 2024, then skyrocketed 237.58% in 2025.
  • Iovance Biotherapeutics' Change in Cash stood at -$152.8 million in 2023, then surged by 68.27% to -$48.5 million in 2024, then surged by 110.23% to $5.0 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Change in Cash are $5.0 million (Q4 2025), $25.7 million (Q3 2025), and -$39.6 million (Q2 2025).